ADC Therapeutics SA
ZYNLONTA
relapsed or refractory diffuse large B-cell lymphoma
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma is in focus around Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“Assuming positive results, we anticipate potential compendia inclusion for each in the first half of 2027 with LOTIS-5 regulatory approvals to follow.”